Prioritising breast cancer theranostics: A current medical longing in oncology

Rainey, 2012, Pharmaceutical patent analyst – FutureScience publishing, World Patent Inf., 34, 317, 10.1016/j.wpi.2012.07.006 Pearce, 2013, Open-source nanotechnology: solutions to a modern intellectual property tragedy, Nano Today, 8, 339, 10.1016/j.nantod.2013.04.001 Paul Oldham, 2016 Anuar, 2013, Patent protections, challenges and applications of nanotechnology, J. Technol. Operat. Manag., 8 Choi, 2020, Qualitative and quantitative analysis of patent data in nanomedicine for bridging the gap between research activities and practical applications, World Patent Information, 60, 10.1016/j.wpi.2019.101943 Young-Ki, 2016, A study on patent valuation important factors: focus on china industry, Indian J. Sci. Technol., 9, 10.17485/ijst/2016/v9i24/96150 Faunce, 2010, Nanosilver and global public health: international regulatory issues, Nanomedicine (London, England), 5, 617, 10.2217/nnm.10.33 Trippe, 2015, Guidelines for preparing patent landscape reports Barabadi, 2019, Emerging theranostic biogenic silver nanomaterials for breast cancer: a systematic review, J. Cluster Sci., 30, 259, 10.1007/s10876-018-01491-7 Zhang, 2013, Nanomaterials in cancer-therapy drug delivery system, J. Biomed. Nanotechnol., 9, 741, 10.1166/jbn.2013.1583 Bhanumathi, 2018, Drug-carrying capacity and anticancer effect of the folic acid- and berberine-loaded silver nanomaterial to regulate the akt-erk pathway in breast cancer, ACS Omega, 3, 8317, 10.1021/acsomega.7b01347 Kim, 2021, Rapid custom prototyping of soft poroelastic biosensor for simultaneous epicardial recording and imaging, Nat. Commun., 12, 3710, 10.1038/s41467-021-23959-3 DeSantis, 2019, Breast cancer statistics, 2019, CA Cancer J. Clin., 69, 438, 10.3322/caac.21583 Saini, 2013, Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer, Cancer Treat. Rev., 39, 935, 10.1016/j.ctrv.2013.03.009 Fang, 2021, 12 Imyanitov, 2004, Mechanisms of breast cancer, Drug Discovery Today, 1, 235, 10.1016/j.ddmec.2004.09.002 Sgouros, 2020, Radiopharmaceutical therapy in cancer: clinical advances and challenges, Nat. Rev. Drug Discovery, 19, 589, 10.1038/s41573-020-0073-9 Wind, 2011, Multidrug resistance in breast cancer: from in vitro models to clinical studies, Int. J. Breast Cancer, 2011, 10.4061/2011/967419 Clarke, 2003, Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling, Oncogene, 22, 7316, 10.1038/sj.onc.1206937 Kim, 2020, Optical spectroscopy for in vivo medical diagnosis—a review of the state of the art and future perspectives, Prog. Biomed. Eng., 2, 10.1088/2516-1091/abaaa3 Benzhong Tang, 2017, 60 Halbert, 2015, 342 Conde, 2015, Implantable hydrogel embedded dark-gold nanoswitch as a theranostic probe to sense and overcome cancer multidrug resistance, Proc. Natl. Acad. Sci., 112, E1278, 10.1073/pnas.1421229112 Partha, 2015, 63 Eroles, 2012, Molecular biology in breast cancer: intrinsic subtypes and signaling pathways, Cancer Treat. Rev., 38, 698, 10.1016/j.ctrv.2011.11.005 Youtie, 2008, Mapping the nanotechnology enterprise: a multi-indicator analysis of emerging nanodistricts in the US South, J. Technol. Transfer, 33, 209, 10.1007/s10961-007-9076-5 Falk, 2017, Patent valuation with forecasts of forward citations, J. Bus. Valuation Econ. Loss Anal., 12, 101, 10.1515/jbvela-2016-0002 M. Gagliardi, "Theranostics: global markets", in: M. Gagliardi (Ed.) BIO198A Theranostics: Global Markets, BCC Research LLC, Boston, USA, 2020, pp. 160. Nogrady, 2020, How cancer genomics is transforming diagnosis and treatment_Nature.pdf, Nature, 579, 10.1038/d41586-020-00845-4 Ghule, 2021, Poly-4-methyl-1-pentene a dielectric material: Patent landscape, J. Energy Storage, 36, 10.1016/j.est.2021.102335 Heather O'NEILL, 2016, 386 David, 2015, Biomarkers for theranostics, 342 David HALBERT, 2018, Aptamers and uses thereof, 219 Hamam, 2017, Circulating microRNAs in breast cancer: novel diagnostic and prognostic biomarkers, Cell Death. Dis., 8, e3045, 10.1038/cddis.2017.440 Roberts, 2020, Advances in oligonucleotide drug delivery, Nat. Rev. Drug Discovery, 19, 673, 10.1038/s41573-020-0075-7 Cerchia, 2010, Targeting cancer cells with nucleic acid aptamers, Trends Biotechnol., 28, 517, 10.1016/j.tibtech.2010.07.005 Xiang, 2015, Nucleic acid aptamer-guided cancer therapeutics and diagnostics: the next generation of cancer medicine, Theranostics, 5, 23, 10.7150/thno.10202 Lakhin, 2013, Aptamers: problems, solutions and prospects, Acta Naturae, 5, 34, 10.32607/20758251-2013-5-4-34-43 Zhou, 2017, Aptamers as targeted therapeutics: current potential and challenges, Nature reviews. Drug discovery, 16, 181, 10.1038/nrd.2016.199 Spetzler, 2012, Circulating Biomarkers, 695 Kuslich, 2011, Circulating biomarkers for disease, 584 Halbert, 2011, Biomarkers for theranostics, 456 Halbert, 2016, Biomarkers for theranostics, 456 Spetzler, 2012, Circulating biomarkers for disease, 639 Brown, 2013, Biomarker compositions and methods, 410 Brown, 2012, Biomarker compositions and methods Thierry, 2012, Analytical methods for cell free nucleic acids and applications, 128 Brown, 2014, Biomarker compositions and methods, 193 SCHETTINI, 2015, 324 Spetzler, 2014, Circulating biomarkers, 507 Giusti, 2013 SCHETTINI, 2014, 464 Maney, 2014, 412 Basilion, 2014, 64 Brown, 2012, Bomarker compositions and markers, 289 Zitvogel, 2018 Spetzler, 2012, Vescle isolation methods, 340 Brown, 2013, 24 Halbert, 2014 Kuslich, 2016, Circulating biomarkers for metastatic prostate cancer, 473 Zeinelden, 2013, 59 Pawlowski, 2014, Circulating biomarkers for cancer, 126 Yan, 2007, Delta-like 4/Notch Signaling and Its Therapeutic Implications, Clin. Cancer Res., 13, 7243, 10.1158/1078-0432.CCR-07-1393 Schwarzenbach, 2011, Cell-free nucleic acids as biomarkers in cancer patients, Nat. Rev. Cancer, 11, 426, 10.1038/nrc3066 Ye, 2015, Argonaute 2: a novel rising star in cancer research, J. Cancer, 6, 877, 10.7150/jca.11735 Zhang, 2014, Galectin-3 as a marker and potential therapeutic target in breast cancer, PLoS One, 9 Ring, 1989, Distribution and physical properties of BCA200, a Mr 200,000 glycoprotein selectively associated with human breast cancer, Cancer Res., 49, 3070 Luk, 2020, Expression and clinical significance of Gal-3 and NFκB pathway-related factors in epithelial ovarian carcinoma, Int. J. Clin. Exp. Pathol., 13, 1197 Panagopoulou, 2020, Phenotypic analysis of extracellular vesicles: a review on the applications of fluorescence, J. Extracellular Vesicles, 9, 10.1080/20013078.2019.1710020 Mayeux, 2004, Biomarkers: Potential uses and limitations, NeuroRX, 182, 10.1602/neurorx.1.2.182 Han, 2017, FOXC1: an emerging marker and therapeutic target for cancer, Oncogene, 36, 3957, 10.1038/onc.2017.48 Afsharzadeh, 2020, PEG-PLA nanoparticles decorated with small-molecule PSMA ligand for targeted delivery of galbanic acid and docetaxel to prostate cancer cells, J. Cell. Physiol., 235, 4618, 10.1002/jcp.29339 Shui, 2019, Gut microbiome as a potential factor for modulating resistance to cancer immunotherapy, Front. Immunol., 10, 2989, 10.3389/fimmu.2019.02989 Konoshenko, 2018, Isolation of extracellular vesicles: general methodologies and latest trends, Biomed. Res. Int., 2018, 10.1155/2018/8545347 Heather O'NEILL, 2016, 386 Heather O'NEILL, 2017, 427 HALBERT, 2018, Nianqing Xiao, aptamers and uses thereof, 219 Mangogna, 2019, Is the complement protein C1q a pro- or anti-tumorigenic factor? Bioinformatics analysis involving human carcinomas, Front. Immunol., 10, 865, 10.3389/fimmu.2019.00865 Kouser, 2015, Emerging and novel functions of complement protein C1q, Front. Immunol., 6, 317, 10.3389/fimmu.2015.00317 Hovanessian, 2010, Surface expressed nucleolin is constantly induced in tumor cells to mediate calcium-dependent ligand internalization, PLoS One, 5, e15787, 10.1371/journal.pone.0015787 Marina, 2014, Cell surface nucleolin as a target for anti-cancer therapies, Recent Patents Anti-Cancer Drug Discovery, 9, 137, 10.2174/1574892808666131119095953